This is a small study involving 190 men in Iran on intermittent ADT. The men were evaluated for metabolic syndrome at six months and a year after starting ADT. The men showed less metabolic syndrome than what has been reported in the literature for men on continuous ADT. This is hardly surprising and consistent with the original push more than a decade ago to use ADT intermittently to reduce of the side effect burden of ADT.
Rezaei MM, Rezaei MM, Ghoreifi A, Kerigh BF. 2016. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen deprivation therapy. Canadian Urological Association Journal 10(9-10):E300-305. www.ncbi.nlm.nih.gov/pubmed/27695584